Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The team identified more than 7,200 babies eligible to have received nirsevimab during its inaugural 2023-24 RSV season. But ...

The new injection, Nirsevimab, will be given to high-risk babies, including those born too early to be protected by the RSV ...

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to ...

Amid an ongoing shortage of nirsevimab, an RSV immunization for young children, the US Centers for Disease Control and Prevention has announced that more than 77,000 additional doses will be ...

Meanwhile, 0.1% of infants in the nirsevimab group and 0.5% of infants in the standard care group were hospitalized for very severe RSV-associated lower respiratory tract infection, with an ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...

In a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis (95% CI 73.4-89.2) in infants younger than 12 months of age, Naim ...

Nirsevimab, a monoclonal antibody to the RSV fusion protein being developed by AstraZeneca and Sanofi, has an extended half-life, which may allow one dose to confer protection throughout a season.

Nirsevimab reduced respiratory syncytial virus lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent 1 Results published in New England Journal of Medicine ...